Printable: How does the FDA approval of next-generation sequencing (NGS) to test for MRD in multiple myeloma affect patients?

How does the FDA approval of next-generation sequencing (NGS) to test for MRD in multiple myeloma affect patients? (https://www.myeloma.org/videos/how-does-fda-approval-next-generation-sequencing-ngs-test-mrd-multiple-myeloma-affect)

In this week’s video, Dr. Durie discusses the two main types of minimal residual disease (MRD) tests for multiple myeloma – next-generation sequencing (NGS) and next-generation flow (NGF).

BOTTOM LINE:
The FDA approval of the NGS test for MRD is excellent news, but this testing is still not ready for use in day-to-day clinical practice.

Author

Dr. Brian GM Durie (https://www.myeloma.org/Brian-Durie-md)

Video

Series

Ask Dr. Durie (https://www.myeloma.org/taxonomy/term/19)

Old Id

1534

Ask a Question

Please note that Ask Dr. Durie has been discontinued, and it was designed to address myeloma questions of the broadest possible audience interest. If you have a question of a personal nature, please contact our InfoLine Coordinators at 800.452.2873 or [email protected] (mailto:[email protected]) (Please do not send email attachments or lab reports.).

Image of Dr. Brian G.M. Durie Dr. Brian G.M. Durie (1942-2025) was the co-founder of the IMF. He was a Professor of Medicine, Hematologist/Oncologist, and Honoree MD at the University of Brussels.